MedTrace Logo

Early Magnetic Resonance Imaging Response of the Dominant Intraprostatic Lesion After Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer and Correlation With Prostate Specific Antigen Response

NCT06822491 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2025-12-23

No results posted yet for this study

Summary

The aim of this phase II study is to determine the early multiparametric magnetic resonance imaging response of the dominant intraprostatic lesion and correlate these findings with prostate specific antigen response in patients with intermediate to (very) high risk localized prostate cancer treated with online adaptive stereotactic radiotherapy without intraprostatic fiducial markers.

Conditions

  • Prostate Carcinoma
  • Localized Prostate Adenocarcinoma
  • Stereotactic Body Radiotherapy
  • Stereotactic Radiotherapy
  • Magnetic Resonance Imaging
  • Multiparametric MRI

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Matthias Guckenberger, Prof. Dr. med. · University of Zurich

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-20
Primary Completion
2026-06-30
Completion
2031-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06822491 on ClinicalTrials.gov